Full-Time

Regulatory Affairs Leader

ENOVIS

ENOVIS

1,001-5,000 employees

Global medical technology company; orthopedic solutions

No salary listed

Rennes, France

In Person

Category
Legal & Compliance (1)
Required Skills
Word/Pages/Docs
Risk Management
Excel/Numbers/Sheets
Requirements
  • At least 5 years of professional experience in regulatory affairs related to medical devices.
  • Management of a strategic project involving multiple departments within the company.
  • Proficiency in European medical device regulations (ideally 2017/745).
  • Knowledge of CE marking procedures and FDA submission processes.
  • Participation in Quality Management System audit (ISO, MDSAP, FDA inspection, etc.).
  • Ability to incorporate requirements related to export registrations, document legalization, etc.
  • Knowledge of ISO 14971
  • Ability to manage cross-functional projects
  • Proficiency in technical English
  • Proficiency in office software (Word, Excel) is required.
  • Organization and autonomy
  • Strong organizational skills with attention to detail and accuracy
  • Ability to work independently and manage priorities effectively
  • Strong communication and writing skills
Responsibilities
  • Ensure technical documentation is complete, maintained, and compliant with applicable regulatory requirements and standards
  • Ensure ongoing compliance once Enovis F&A devices are placed on the market
  • Validate regulatory content in technical files, IFUs, labeling, and marketing materials
  • Coordinate and contribute to product risk management activities (ISO 14971)
  • Maintain consistency, integrity, and updates of technical dossiers
  • Define and implement regulatory registration strategies
  • Ensure integration of export requirements (legalization, registrations, etc.)
  • Manage regulatory submissions and renewals (CE marking, 510(k), export certifications, etc.)
  • Ensure compliance with market authorization requirements and lifecycle management
  • Submit required periodic reports to competent authorities
  • Conduct regulatory impact assessments for product, process, and system changes
  • Ensure implementation of required regulatory actions following gap analyses
  • Contribute to post-market surveillance activities (PMS, PSUR, PMSR)
  • Maintain regulatory data in internal and external databases
  • Manage regulatory aspects of product availability (ERP “blocking/unblocking”)
  • Act as regulatory contact for customers, distributors, notified bodies, suppliers, and internal teams
  • Manage communication with competent authorities regarding regulatory matters
  • Support and manage regulatory aspects of distributor quality agreements
  • Inform internal and external stakeholders of regulatory changes
  • Participate in notified body and regulatory audits
  • Manage regulatory requirements within ISO 13485 QMS and 21 CFR Part 820 frameworks
  • Support product release activities, including batch dossier approval

Enovis develops medical devices and services to improve patient outcomes and restore mobility. It operates Prevention & Recovery with orthopedic braces, soft goods, vascular therapy, compression garments, and hot/cold therapy, and Reconstructive with joint implants and surgical tools such as Novastep. It differentiates itself through a broad clinically oriented portfolio, a global footprint, and the EGX continuous improvement program, plus the LimaCorporate acquisition expanding its transatlantic reach. Its goal is to provide better patient outcomes and mobility worldwide through sustained growth and operational excellence.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Extremities segment achieves 10% organic growth led by double-digit shoulder gains.
  • ARVIS robot deployment starts with South Africa procedure, adoption expands through 2026.
  • BTIG initiates Buy rating with $41 target on new launches in hips and knees.

What critics are saying

  • $1.18B goodwill impairment from LimaCorporate overpayment erodes R&D capital now.
  • Stryker Mako captures 60% US robotic shoulder procedures, blocks ARVIS adoption by 2027.
  • Zimmer Biomet Persona IQ steals Nebula conversions, slows recon growth by mid-2027.

What makes ENOVIS unique

  • Enovis leverages Enovis Growth Excellence system for continuous operational improvements.
  • Enovis offers ARVIS shoulder robot and Augmented Reverse Glenoid System for extremities.
  • Enovis integrates LimaCorporate acquisition to expand reconstructive implant portfolio.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at ENOVIS who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Legal Services

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

32%
Yahoo Finance
Feb 28th, 2026
Enovis reports strong revenue growth and new device uptake despite $1.18B goodwill impairment

Enovis Corporation has reported strong organic revenue growth driven by new product launches, including the Nebula Stem and OrthoDrive Impactor, which have seen rapid market uptake. The medical technology company's devices are gaining traction with surgeons and hospitals. However, Enovis recorded a significant goodwill impairment charge in its fourth quarter and full-year results, affecting its balance sheet. The impairment raises questions about returns from previous acquisitions and future capital allocation strategy. Trading at $25.47, Enovis shares are approximately 44% below the analyst price target of $45.18. The company currently shows a loss of $1.18 billion and trades at a forward price-to-earnings ratio of 25.73 times. Investors are advised to monitor how product adoption and procedure volumes affect future cash flow.

Yahoo Finance
Feb 26th, 2026
Enovis stock jumps 12.6% on strong 2026 earnings forecast despite Q4 revenue miss

Enovis Corporation shares jumped 12.6% in morning trading after the medical technology company reported mixed fourth-quarter results but issued a strong earnings forecast for 2026. Whilst quarterly revenue of approximately $576 million missed expectations, adjusted earnings per share of $0.95 beat analyst estimates. The stock surge was driven by Enovis's 2026 earnings guidance of $3.52 to $3.73 per share, with the midpoint significantly exceeding analyst projections. This positive profit outlook overshadowed the revenue shortfall. Enovis shares have experienced high volatility, with 26 moves exceeding 5% over the past year. The stock is down 6.6% year-to-date and trading 38.1% below its 52-week high of $40 from March 2025.

Yahoo Finance
Feb 26th, 2026
Enovis reports $520.6M Q4 loss despite adjusted earnings of 95 cents per share

Enovis Corporation reported a fourth-quarter loss of $520.6 million, or $9.10 per share. The Wilmington, Delaware-based manufacturing and engineering company posted adjusted earnings of 95 cents per share, excluding asset impairment and non-recurring costs. Revenue for the quarter reached $575.8 million. For the full year, Enovis reported a loss of $1.18 billion, or $20.75 per share, on revenue of $2.25 billion.

Yahoo Finance
Jan 23rd, 2026
BTIG initiates Enovis with $41 target as orthopedic tech firm eyes growth from new product launches

Enovis Corporation has received positive analyst coverage, with BTIG initiating a Buy rating and $41 price target on 6 January. The orthopedic care company is expected to see accelerated growth in 2026 driven by new product launches across extremities, hips and knees. BTIG highlighted the company's consistent mid-to-high single-digit organic revenue growth in its Reconstruction and Prevention & Recovery segments. The higher-growth Reconstruction business is expected to drive margins whilst the mature Prevention & Recovery segment delivers steady cash flow. UBS maintained its Buy rating but lowered its price target to $50 from $57, projecting sales of $2.26 billion in 2025, $2.37 billion in 2026 and $2.52 billion in 2027.

TradingView
Dec 10th, 2025
Enovis secures $700M term loan and $1.1B credit facility, extends maturity to 2030

Enovis Corp has entered Amendment No. 3 to its credit agreement on 8 December, extending the loan maturity date to 8 December 2030. The amended agreement provides a revolving credit facility of up to $1.1 billion and a term loan facility of $700 million. The company used term loan proceeds to repay $335 million from its revolving facility. The amendment restructures Enovis's debt arrangements, providing the medical technology company with extended financing flexibility through the end of the decade.